Cas:1131335-72-2 6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine manufacturer & supplier

Chemical Name:6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine

CAS.NO:1131335-72-2

Synonyms:A-5967;6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine

Molecular Formula:C₁₀H₁₂BrNOSi

Molecular Weight:270.19800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:26.03000

Exact Mass:268.98700

LogP:3.13550

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like A-5967 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine Use and application,6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine technical grade,usp/ep/jp grade.

Related News: Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine manufacturer However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. 6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine supplier As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine vendor As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 6-Bromo-2-(trimethylsilyl)furo[3,2-b]pyridine factory As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.